East New Britain Province Monitoring & Evaluation

CompletedOBSERVATIONAL
Enrollment

12,930

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2024

Conditions
Lymphatic Filariasis Elimination by Mass Drug AdministrationMonitoring and Evaluation of Mass Drug Administration for Lymphatic FilariasisAcceptability of Mass Drug Administration for Lymphatic Filariasis
Interventions
OTHER

Observational

Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years

Trial Locations (1)

Unknown

East New Britain Provincial Health Authority, Kokopo

All Listed Sponsors
collaborator

Case Western Reserve University

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Papua New Guinea Institute for Medical Research

UNKNOWN

collaborator

Papua New Guinea ENB Provincial Health Authority

UNKNOWN

collaborator

Papua New Guinea National Department of Health

UNKNOWN

lead

University Hospitals Cleveland Medical Center

OTHER

NCT04124250 - East New Britain Province Monitoring & Evaluation | Biotech Hunter | Biotech Hunter